Hypnosis Versus Placebo During Atrial Flutter Ablation: The PAINLESS Study: A Randomized Controlled Trial.


Journal

JACC. Clinical electrophysiology
ISSN: 2405-5018
Titre abrégé: JACC Clin Electrophysiol
Pays: United States
ID NLM: 101656995

Informations de publication

Date de publication:
11 2020
Historique:
received: 25 02 2020
revised: 06 05 2020
accepted: 26 05 2020
entrez: 20 11 2020
pubmed: 21 11 2020
medline: 19 8 2021
Statut: ppublish

Résumé

The aim of this study was to assess the superiority of hypnosis versus placebo on pain perception and morphine consumption during typical atrial flutter (AFL) ablation. AFL ablation commonly requires intravenous opioid for analgesia, which can be associated with adverse outcomes. Hypnosis is an alternative technique with rising interest, but robust data in electrophysiological procedures are lacking. This single center, randomized controlled trial compared hypnosis and placebo during AFl ablation. In addition to the randomized intervention, all patients were treated according to the institution's standard of care analgesia protocol (administration of 1 mg of intravenous morphine in case of self-reported pain ≥5 on an 11-point numeric rating scale or on demand). The primary endpoint was perceived pain quantified by patients using a visual analog scale. Between October 2017 and September 2019, 113 patients (mean age 70 ± 12 years, 21% women) were randomized to hypnosis (n = 56) or placebo (n = 57). Mean pain score was 4.0 ± 2.2 in the hypnosis group versus 5.5 ± 1.8 in the placebo group (p < 0.001). Pain perception, assessed every 5 min during the whole procedure, was consistently lower in the hypnosis group. Patients' sedation scores were also better in the hypnosis group than in the placebo group (8.3 ± 2.2 vs. 5.4 ± 2.5; p < 0.001). Finally, morphine requirements were significantly lower in the hypnosis group (1.3 ± 1.3 mg) compared with the placebo group (3.6 ± 1.8 mg; p < 0.001). In this first randomized trial, hypnosis during AFL ablation was superior to placebo for alleviating pain and reducing morphine consumption.

Sections du résumé

OBJECTIVES
The aim of this study was to assess the superiority of hypnosis versus placebo on pain perception and morphine consumption during typical atrial flutter (AFL) ablation.
BACKGROUND
AFL ablation commonly requires intravenous opioid for analgesia, which can be associated with adverse outcomes. Hypnosis is an alternative technique with rising interest, but robust data in electrophysiological procedures are lacking.
METHODS
This single center, randomized controlled trial compared hypnosis and placebo during AFl ablation. In addition to the randomized intervention, all patients were treated according to the institution's standard of care analgesia protocol (administration of 1 mg of intravenous morphine in case of self-reported pain ≥5 on an 11-point numeric rating scale or on demand). The primary endpoint was perceived pain quantified by patients using a visual analog scale.
RESULTS
Between October 2017 and September 2019, 113 patients (mean age 70 ± 12 years, 21% women) were randomized to hypnosis (n = 56) or placebo (n = 57). Mean pain score was 4.0 ± 2.2 in the hypnosis group versus 5.5 ± 1.8 in the placebo group (p < 0.001). Pain perception, assessed every 5 min during the whole procedure, was consistently lower in the hypnosis group. Patients' sedation scores were also better in the hypnosis group than in the placebo group (8.3 ± 2.2 vs. 5.4 ± 2.5; p < 0.001). Finally, morphine requirements were significantly lower in the hypnosis group (1.3 ± 1.3 mg) compared with the placebo group (3.6 ± 1.8 mg; p < 0.001).
CONCLUSIONS
In this first randomized trial, hypnosis during AFL ablation was superior to placebo for alleviating pain and reducing morphine consumption.

Identifiants

pubmed: 33213815
pii: S2405-500X(20)30467-9
doi: 10.1016/j.jacep.2020.05.028
pii:
doi:

Substances chimiques

Analgesics, Opioid 0
Morphine 76I7G6D29C

Types de publication

Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

1551-1560

Informations de copyright

Copyright © 2020 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Author Relationship With Industry Dr. Garcia has received consulting fees from St. Jude Medical and Boston Scientific. Drs. Le Gal and Degand have received consulting fees from Sorin Group, St. Jude Medical, and Boston Scientific. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Auteurs

Rodrigue Garcia (R)

Centre Hospitalier Universitaire (CHU) Poitiers, Cardiology Department, Poitiers, France; Université de Poitiers, Faculté de Médecine et Pharmacie, Poitiers, France. Electronic address: rodrigue.garcia@chu-poitiers.fr.

Claire Bouleti (C)

Centre Hospitalier Universitaire (CHU) Poitiers, Cardiology Department, Poitiers, France; Université de Poitiers, Faculté de Médecine et Pharmacie, Poitiers, France; INSERM CIC 1402, Poitiers, France.

Anthony Li (A)

Cardiology Clinical Academic Group, St. George's University of London, London, United Kingdom.

Denis Frasca (D)

Université de Poitiers, Faculté de Médecine et Pharmacie, Poitiers, France; Centre Hopsitalier Universitaire (CHU) Poitiers, Anesthesia and Intensive Care, Poitiers, France.

Sophia El Harrouchi (S)

Centre Hospitalier Universitaire (CHU) Poitiers, Cardiology Department, Poitiers, France.

Julien Marechal (J)

Centre Hospitalier Universitaire (CHU) Poitiers, Cardiology Department, Poitiers, France.

Pierre Roumegou (P)

Centre Hospitalier Universitaire (CHU) Poitiers, Cardiology Department, Poitiers, France.

Pierre Corbi (P)

Université de Poitiers, Faculté de Médecine et Pharmacie, Poitiers, France; Centre Hospitalier Universitaire (CHU) Poitiers, Department of Thoracic and Cardiovascular Surgery, Poitiers, France.

Luc Christiaens (L)

Centre Hospitalier Universitaire (CHU) Poitiers, Cardiology Department, Poitiers, France; Université de Poitiers, Faculté de Médecine et Pharmacie, Poitiers, France.

François Le Gal (F)

Centre Hospitalier Universitaire (CHU) Poitiers, Cardiology Department, Poitiers, France.

Bruno Degand (B)

Centre Hospitalier Universitaire (CHU) Poitiers, Cardiology Department, Poitiers, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH